COMMUNIQUÉS West-GlobeNewswire

NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373
13/09/2017
Received Best Poster Presentation Award at ESMO 2017 EDINBURGH, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- NuCana plc announced the presentation of interim first-in-human data from a Phase 1 clinical study of [...]
Soliqua® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL
13/09/2017
Press release - No. 7/2017 Soliqua ® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL More adults reached HbA 1c target at 8 and 12 weeks versus those receiving insulin glargine 100 units/ [...]
Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer
13/09/2017
Heidelberg, Germany, September 13, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the [...]
Nicox : Rapport semestriel financier au 30 juin 2017
13/09/2017
Communiqué de presse Nicox : Rapport semestriel financier au 30 juin 2017 13 septembre 2017 Sophia Antipolis, France Le Rapport Semestriel Financier et d'Activité de la société Nicox S.A. au 30 juin 2017 visé à l' [...]
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
13/09/2017
Cosentyx ® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI 90 and PASI 100 response rates were [...]
Biocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
13/09/2017
PRESS RELEASE: REGULATED - INSIDE INFORMATION Wednesday September 13, 2017, 07:00 CEST Tuesday September 12, 2017, 22:00 PT Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX ® [...]
Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials
12/09/2017
Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD DUBLIN and LAS VEGAS - September 12, 2017 - Medtronic plc (NYSE: MDT) data announced today reinforce the durability [...]
Deinove : Le projet « AGIR » obtient une aide de 14,6 millions d'euros du PIA
12/09/2017
Communiqué de presse 12 SEPTEMBRE 2017 Le projet « AGIR » porté par le groupe DEINOVE bénéficie d'une aide de 14,6 millions d'euros du Programme d'Investissements d'Avenir (PIA) opéré par Bpifrance pour développer de [...]
Deinove : The AGIR project carried out by the DEINOVE group is granted €14.6 m
12/09/2017
Press release 12 September 2017 The AGIR project carried out by the DEINOVE group is granted €14.6 million by the 'Investments for the Future' Program (IFP) operated by Bpifrance to develop new antibiotics. The AGIR [...]
Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
12/09/2017
Oslo, Norway, 12 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start of patient [...]
Medtronic Announces New StealthStation(TM) Technology for Ear, Nose, and Throat Procedures
12/09/2017
New Platform to Offer Enhanced Visualization and Increased Efficiency for Surgery of the Sinuses and Skull Base DUBLIN - September 12, 2017 - Medtronic plc (NYSE: MDT) today announced the global launch of the [...]
MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
12/09/2017
MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics Broad collaboration to develop a targeted Next-Generation Sequencing assay for microbial infections Workflow for native samples integrating MGI [...]
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
12/09/2017
Lisbon, Portugal, 12 September 2017 - A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA 1c and [...]
Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term
12/09/2017
Lisbon, Portugal, 12 September 2017 - Fiasp ® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting 1-3 mealtime insulin, improved overall blood sugar (HbA 1c ) and post-meal sugar ( [...]
Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants
12/09/2017
Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants Cambridge, Mass. - September 12, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the biotech [...]
NuCana Announces Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017
12/09/2017
Acelarin combination with carboplatin achieved 96% disease control rate and 39% response rate in patients with recurrent ovarian cancer EDINBURGH, United Kingdom, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NuCana plc, a [...]
AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME
12/09/2017
AC Immune completes Recruitment for Low-Dose Cohort of Participants in World's First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer's Disease-like Characteristics in Individuals with Down Syndrome Phase 1b [...]
Saniona AB: Saniona presents Tesomet Phase 2 data at the EASD Congress
12/09/2017
PRESS RELEASE September 12, 2017 Saniona, a leading biotech company in the field of ion channels, today announces that the promising data from its Phase 2a study with Tesomet in type 2 diabetes has been selected for two [...]
PCI Biotech: Initial clinical results from Phase I indicate that vaccination with fimaVACC enhances cellular immune responses
12/09/2017
Oslo (Norway), 12 September 2017 - PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the first immune [...]

Pages